Cargando…
Pre-hypertension: another ‘pseudodisease’?
Hypertension is one of the most important and common cardiovascular risk factors. Defining the level at which blood pressure starts causing end-organ damage is challenging, and is not easily answered. The threshold of blood pressure defining hypertension has progressively been reduced over time, fro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848832/ https://www.ncbi.nlm.nih.gov/pubmed/24229371 http://dx.doi.org/10.1186/1741-7015-11-211 |
_version_ | 1782293830629851136 |
---|---|
author | Meier, Pascal Messerli, Franz H Baumbach, Andreas Lansky, Alexandra J |
author_facet | Meier, Pascal Messerli, Franz H Baumbach, Andreas Lansky, Alexandra J |
author_sort | Meier, Pascal |
collection | PubMed |
description | Hypertension is one of the most important and common cardiovascular risk factors. Defining the level at which blood pressure starts causing end-organ damage is challenging, and is not easily answered. The threshold of blood pressure defining hypertension has progressively been reduced over time, from systolic >160 mmHg to >150 mmHg, then to >140 mmHg; and now even blood pressures above 130 to 120 mmHg are labeled as ‘pre-hypertension’ by some expert committees. Are interest groups creating another ‘pseudodisease’ or is this trend scientifically justified? A recent meta-analysis published in BMC Medicine by Huang et al. clearly indicates that pre-hypertension (120 to 140/80 to 90 mmHg) is a significant marker of increased cardiovascular risk. This raises the question as to whether we now need to lower the threshold of ‘hypertension’ (as opposed to ‘pre-hypertension’) to >120/80 mmHg, redefining a significant proportion of currently healthy people as ‘patients’ with an established disease. These data need to be interpreted with some caution. It is controversial whether pre-hypertension is an independent risk factor or just a risk marker and even more controversial whether treatment of pre-hypertension will lower cardiovascular risk. Please see related research: http://www.biomedcentral.com/1741-7015/11/177. |
format | Online Article Text |
id | pubmed-3848832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38488322013-12-09 Pre-hypertension: another ‘pseudodisease’? Meier, Pascal Messerli, Franz H Baumbach, Andreas Lansky, Alexandra J BMC Med Commentary Hypertension is one of the most important and common cardiovascular risk factors. Defining the level at which blood pressure starts causing end-organ damage is challenging, and is not easily answered. The threshold of blood pressure defining hypertension has progressively been reduced over time, from systolic >160 mmHg to >150 mmHg, then to >140 mmHg; and now even blood pressures above 130 to 120 mmHg are labeled as ‘pre-hypertension’ by some expert committees. Are interest groups creating another ‘pseudodisease’ or is this trend scientifically justified? A recent meta-analysis published in BMC Medicine by Huang et al. clearly indicates that pre-hypertension (120 to 140/80 to 90 mmHg) is a significant marker of increased cardiovascular risk. This raises the question as to whether we now need to lower the threshold of ‘hypertension’ (as opposed to ‘pre-hypertension’) to >120/80 mmHg, redefining a significant proportion of currently healthy people as ‘patients’ with an established disease. These data need to be interpreted with some caution. It is controversial whether pre-hypertension is an independent risk factor or just a risk marker and even more controversial whether treatment of pre-hypertension will lower cardiovascular risk. Please see related research: http://www.biomedcentral.com/1741-7015/11/177. BioMed Central 2013-09-25 /pmc/articles/PMC3848832/ /pubmed/24229371 http://dx.doi.org/10.1186/1741-7015-11-211 Text en Copyright © 2013 Meier et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Meier, Pascal Messerli, Franz H Baumbach, Andreas Lansky, Alexandra J Pre-hypertension: another ‘pseudodisease’? |
title | Pre-hypertension: another ‘pseudodisease’? |
title_full | Pre-hypertension: another ‘pseudodisease’? |
title_fullStr | Pre-hypertension: another ‘pseudodisease’? |
title_full_unstemmed | Pre-hypertension: another ‘pseudodisease’? |
title_short | Pre-hypertension: another ‘pseudodisease’? |
title_sort | pre-hypertension: another ‘pseudodisease’? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848832/ https://www.ncbi.nlm.nih.gov/pubmed/24229371 http://dx.doi.org/10.1186/1741-7015-11-211 |
work_keys_str_mv | AT meierpascal prehypertensionanotherpseudodisease AT messerlifranzh prehypertensionanotherpseudodisease AT baumbachandreas prehypertensionanotherpseudodisease AT lanskyalexandraj prehypertensionanotherpseudodisease |